Home › Research › Health systems and care delivery
Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA-DEM cohort
Couret Anaïs, Gardette Virginie, Renoux Axel, Lapeyre-Mestre Maryse. British journal of clinical pharmacology, 2024-06-27
Topic: Risk, prevention and care in population studies
Plain-language summary
Alzheimer's disease and related diseases (ADRD) is a progressive and inexorable disease. In France, acetylcholinesterase inhibitors and memantine were reimbursed for subjects with ADRD, until 2 modifications of their reimbursement rate (2012, 2018). We aimed to study the consequences of these measures on ADRD subjects' healthcare use. We analysed data from the FRA-DEM cohort, including subjects with presumed incident ADRD identified since 2011 in the French health insurance system. We studied the healthcare use of subjects identified with incident ADRD in 2011, 2013, 2015, 2017 and 2019, notably the annual number of defined daily doses of various psychotropic groups. We performed 2 multivariate multinomial logistic regressions with the subcohort year as the dependent variable. In total, 165 120 subjects were included. A progressive decrease in exposure to antidementia drugs was observed between 2011 and 2019. Consultations with private neurologists or psychiatrists, and exposure to risperidone, antidepressants and benzodiazepines increased in the 2019 subcohort, following the 2018 reimbursement withdrawal. Meanwhile, the use of nursing/allied healthcare and emergency care increased over the subcohort years, whereas we observed a decrease in general practitioner consultations. These results suggest increases in private neurologist or psychiatrist consultations and exposure to recommended drugs after the reimbursement withdrawal, contrary to the fears expressed. However, antidementia drug exposure decreased long before the reimbursement modifications, probably due to the growing evidence of the modest effect of these drugs, and exposure to benzodiazepines increased after the reimbursement withdrawal.
What this study adds
Evidence grade: Moderate
The record lists 120 participants. This study analyzed the consequences of changes to antidementia drug reimbursement in France on healthcare use. It found increases in private neurologist or psychiatrist consultations and exposure to recommended drugs after the reimbursement withdrawal, contrary to fears expressed, but does not test any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Anaïs, C., Virginie, G., Axel, R., & Maryse, L.-M. (2024). Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA-DEM cohort. British journal of clinical pharmacology. https://doi.org/10.1111/bcp.16143
Vancouver
Anaïs C, Virginie G, Axel R, Maryse L.-M. Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA-DEM cohort. British journal of clinical pharmacology. 2024. doi:10.1111/bcp.16143. PMID: 38925159.
BibTeX
@article{anais2024-38925159,
author = {Anaïs, Couret and Virginie, Gardette and Axel, Renoux and Maryse, Lapeyre-Mestre},
title = {{Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA-DEM cohort}},
journal = {British journal of clinical pharmacology},
year = {2024},
doi = {10.1111/bcp.16143},
pmid = {38925159},
url = {https://doi.org/10.1111/bcp.16143}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Meanwhile, the use of nursing/allied healthcare and emergency care increased over the subcohort years, whereas we observed a decrease in general practitioner consultations.
- These results suggest increases in private neurologist or psychiatrist consultations and exposure to recommended drugs after the reimbursement withdrawal, contrary to the fears expressed.
Why it matters
This study analyzed the consequences of changes to antidementia drug reimbursement in France on healthcare use. It found increases in private neurologist or psychiatrist consultations and exposure to recommended drugs after the reimbursement withdrawal, contrary to fears expressed, but does not test any treatment, cure, or prevention.
Study details
- Participants120
- Evidence strengthModerate
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (British journal of clinical pharmacology) |
| Journal's citation record | 2 / 4 | British Journal of Clinical Pharmacology: journal h-index 221 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 120 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 1 / 6 | Cited 0.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Maryse Lapeyre‐Mestre: h-index 59 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38925159) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1111/bcp.16143
- PubMed: 38925159
- Original source →
- Free full text: British Journal of Clinical Pharmacology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.